Bapineuzumab and solanezumab for Alzheimer's disease: Is the 'amyloid cascade hypothesis' still alive?

Expert Opinion on Biological Therapy

Volumn 13, Issue 7, 2013, Pages 1075-1084

  Tayeb, Haythum O ^a,b   Murray, Evan D ^a   Price, Bruce H ^a   Tarazi, Frank I ^a  

^a MCLEAN HOSPITAL   (United States)

^b King Abdulaziz University   (Saudi Arabia)

Author keywords

Alzheimer's disease; Amyloid cascade; Bapineuzumab; Clinical trials; Cognitive functions; Safety and tolerability; Solanezumab

Indexed keywords

ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BAPINEUZUMAB; CAD 106; DONEPEZIL; GALANTAMINE; HEMOSIDERIN; HOMOTAURINE; MEMANTINE; MPC 7869]; PLACEBO; PRESENILIN 1; PRESENILIN 2; RIVASTIGMINE; SEMAGACESTAT; SOLANEZUMAB; TARENFLURBIL; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANGINA PECTORIS; BRAIN EDEMA; BRAIN SIZE; COGNITION; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MOLECULAR MIMICRY; NERVOUS SYSTEM INFLAMMATION; OXIDATIVE STRESS; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN METABOLISM; REVIEW; SENILE PLAQUE; SINGLE DRUG DOSE; TREATMENT DURATION; VACCINATION;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOTHERAPY;

EID: 84878927746     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.789856     Document Type: Review

References (87)

1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186-91
3. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 2011;7(2):208-44
4. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768-78
5. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004;25:641-50
6. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2012; In press
7. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2012;In press
8. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-81
9. Cechetto DF, Hachinski V, Whitehead SN. Vascular risk factors and Alzheimer's disease. Expert Rev Neurother 2008;8:743-50
10. Xu WL, von Strauss E, Qiu CX, et al. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 2009;52:1031-9
11. Galbussera A, Tremolizzo L, Isella V, et al. Lack of evidence for Borrelia burgdorferi seropositivity in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:308
12. Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease? Nat Rev Neurosci 2010;11:361-70
13. Ring R, Lyons J. Failure to detect Chlamydophila pneumoniae in late onset Alzheimer's brain. J Clin Microbiol 2000;38:2591-4
14. Holmes C, Cotterell D. Role of infection in the pathogenesis of Alzheimer's disease, implications for treatment. CNS Drugs 2009;23:993-1002
15. Graves A, Van Duijn C, Chandra V, et al. Occupational exposures to solvents and lead as risk factors for Alzheimer's disease. Int J Epidemiol 1991;20(Suppl 2):S58-61
16. Yaffe K. Antioxidants and prevention of cognitive decline: does duration of use matter? Arch Intern Med 2007;167:2167-8
17. Kumar V, Kinsella L. Healthy brain aging: effect of head injury, alcohol and environmental toxins. Clin Geriatr Med 2010;26:29-44
18. Matthews BR. Alzheimer disease update. Continuum (Minneap Minn) 2010;16(2 Dementia):15-30
19. Vemuri P, Wiste H, Weigand S, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73:294-301
20. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92
21. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5
22. Selkoe D, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-84
23. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004;101:4637-42
24. Furukawa K, Sopher B, Rydel R, et al. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 1996;67:1882-96
25. Gandy S, Martins R, Buxbaum J. Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:259-66
26. Rosenberg R. Translational research on the way to effective therapy for Alzheimer disease. Arch Gen Psychiatry 2005;62:1186-92
27. Cummings J. Alzheimer's disease. N Engl J Med 2004;351:56-67
28. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002;68:209-45
29. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:583-95
30. Shah RS, Lee H-G, Xiongwei Z, et al. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 2008;62:199-207
31. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062-4
32. Knopman DS. Mild cognitive impairment and on to dementia: down the slippery slope but faster. Neurology 2010;74:942-4
33. Hoozemans J, Veerhuis R, Rozemuller J, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 2006;24:157-65
34. King ME, Kan HM, Baas PW, et al. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 2006;175:541-6
35. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q as a potential treatment. J Bioenerg Biomembr 2004;36:381-6
36. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005;58:495-505
37. Carlson CM. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis 2010;20:711-22
38. Craft S. The role of insulin dysregulation in aging and Alzheimer's disease. In: Craft S, Christen Y, editors. Diabetes, insulin and Alzheimer's disease. Springer; Berlin Heidelberg: 2010. p. 109-27
39. Luchsinger JA, Tang M-X, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60:203-8
40. Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 2012;134:8-25
41. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gammasecretase- like protease mediates release of Notch intracellular domain. Nature 1999;398:518-22
42. Wong G, Manfra D, Poulet F, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82
43. Clinicaltrials.gov. Effect of LY450139 on the long term progression of Alzheimer's disease [IDENTITY 1]. Clinicaltrials.gov identifier NCT-00594568
44. Clinicaltrials.gov. Effects of LY450139, on the progression of Alzheimer's disease as compared with placebo [IDENTITY 2]. Clinicaltrials.gov identifier NCT-00762411
45. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64
46. Galasko D, Graff-Radford N, May S, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007;21:292-9
47. Martone RL, Zhou H, Atchison K, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009;331:598-608
48. Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001;8(Suppl 1):28-35
49. Aisen P, Gauthier S, Ferris S, et al. Tramiprosate in mild-to-moderate Alzheimer's disease-a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011;7:102-11
50. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
51. Orgogozo J, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
52. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-52
53. Ferrer I, Rovira MB, Guerra MLS, et al. Neuropathology and pathogenesis of encephalitis following amyloid beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20
54. Maier M, Seabrook TJ, Lazo ND, et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006;26:4717-28
55. ClinicalTrials.Gov. Safety, tolerability and Abeta-specific antibody response of repeated i.m. injections of adjuvanted CAD106 in mild Alzheimer patients. ClinicalTrialsgov identifier: NCT01097096
56. ClinicalTrials.Gov. To investigate the safety and tolerability of repeated subcutaneous injections of CAD106 in Alzheimer's patients. Clinicaltrialsgov identifier: NCT00956410
57. Lombardo JA, Stern EA, McLellan ME, et al. Amyloid beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003;23:10879-83
58. Brendza RP, Bacskai BJ, Cirrito JR, et al. Anti-A beta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005;115:428-33
59. Dodart J-C, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-7
60. Walsh DM, Selkoe DJ. Abeta oligomers - a decade of discovery. J Neurochem 2007;101:1172-84
61. Panza F, Frisardi V, Imbimbo BP, et al. Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy 2010;2:767-82
62. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198-203
63. Panza F, Frisardi V, Imbimbo BP, et al. Monoclonal antibodies against -amyloid (A) for the treatment of Alzheimer's disease: the A target at a crossroads. Expert Opin Biol Ther 2011;11:679-86
64. ClinicalTrials.Gov. A long-term safety and tolerability study of bapineuzumab in Alzheimer disease patients. ClinicalTrialsgov identifier: NCT00667810
65. ClinicalTrials.Gov. A long-term safety and tolerability extension study of bapineuzumab in Alzheimer disease patients. Clinicaltrialsgov identifier: NCT00676143
66. ClinicalTrials.Gov. Study evaluating the long-term safety and efficacy of subcutaneous Bapineuzumab. ClinicalTrialsgov identifier: NCT00916617
67. Johnson and Johnson Press Release. Johnson and Johnson announces discontinuation of phase 3 development of Bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease. Press Release; August 6, 2012
68. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
69. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-85
70. Seubert P, Barbour R, Khan K, et al. Antibody capture of soluble A beta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008;5:65-71
71. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma Abeta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-5
72. DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264-7
73. Siemers E, Friedrich S, Dean R. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
74. Farlow M AS, van Dyck CH, Aisen PS, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012(8):261-71
75. ClinicalTrials.Gov. Effect of LY2062430 on the progression of Alzheimer's disease (EXPEDITION 1). Clinicaltrialsgov identifier: NCT00905372
76. ClinicalTrials.Gov. Effect of LY2062430 on the progression of Alzheimer's disease (EXPEDITION 2). Clinicaltrialsgov identifier: NCT00904683
77. Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther 2011;11:787-98
78. ClinicalTrials.Gov. Continued safety monitoring of Solanezumab in Alzheimer's disease (EXPEDITION EXT). Clinicaltrialsgov identifier: NCT01127633
79. Eli Lilly press release. Eli Lilly and Co. announces top-line results on solanezumab phase 3 clinical trials in patients with Alzheimer's Disease. Press release, October 8, 2012
80. The Clinical Trials in Alzheimer's Disease (CTAD) press release. Independent analysis of solanezumab provides evidence that compound may remove amyloid from brain in Alzheimer's disease. Press release, October 29, 2012
81. Lee HG, Casadesus G, Zhu X, et al. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer's disease. Ann NY Acad Sci 2004;1019:1-4
82. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9
83. Reiman EM, Langbaum JB, Tariot PN. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010;4:3-14
84. Banner Health Press Release. Groundbreaking Alzheimer's disease prevention trial announced. Press Release, May 15, 2012
85. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the dominantly inherited Alzheimer network. Clin Investig 2012;2:975-84
86. Washington University in St. Louis Press Release. Investigational drugs chosen for major Alzheimer's prevention trial. Press Release October 10, 2012
87. Alzheimer's Association International Conference. New methods reported for safely and accurately disclosing Alzheimer's disease risk based on newly approved tests. AAIC Press Release, July 17, 2012